



## Board Member R. Scott Huennekens Not Standing for Re-Election

**Sydney, Australia and San Diego, California** (Tuesday, 27 March 2018, AEDT) – REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular medical applications, announced that on March 22, 2018, R. Scott Huennekens, who is a Class II member of the board of directors of REVA Medical, Inc. (the “Company”) and whose three-year term is expiring at the Company’s 2018 annual meeting, informed the Company that he does not intend to stand for re-election at the 2018 annual meeting due to his other time commitments. Mr. Huennekens’ decision to resign was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices.

“Scott has been a fantastic board member who helped us tremendously as we transitioned from research and development to commercialization,” said Reggie Groves, Chief Executive Officer. “We are thankful for his years of service and wish him well with his many professional endeavors. From a board perspective, we have numerous members with commercialization experience and Dr. Stephen N. Oesterle, who joined our board in February 2018, is an interventional cardiologist with extensive experience in the coronary market. We look forward to working with our board as we move forward with commercialization of Fantom and Fantom Encore.”

### About REVA Medical

REVA Medical is a medical device company focused on the development and commercialization of bioresorbable polymer technologies for vascular applications. The Company’s lead products are the Fantom and Fantom Encore bioresorbable vascular scaffolds for the treatment of coronary artery disease. REVA is located in San Diego, California, USA and employs over 50 people in the U.S. and Europe.

Fantom, Fantom Encore, and Tyrocore are trademarks of REVA Medical, Inc.

### Forward-Looking Statements

*This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions, and expectations and on information currently available to management. All statements that are not statements of historical fact, including those statements that address future operating plans or performance and events or developments that may occur in the future, are forward-looking statements, such as those statements regarding the projections and timing surrounding commercial operations and sales, clinical trials, pipeline product development, and future financings. No undue reliance should be placed on forward-looking statements. Although management believes forward-looking statements are reasonable as and when made, forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to vary materially from those expressed in forward-looking statements, including the risks and uncertainties that are described in the "Risk Factors" section of our Annual Report on Form 10-K filed with the US Securities and Exchange Commission (the "SEC") on March 7, 2018, and as updated in our periodic reports thereafter. Any forward-looking statements in this announcement speak only as of the date when made. REVA does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.*

**United States****Investor & Media Enquiries:**

REVA Medical, Inc.  
Brandi Roberts  
Chief Financial Officer  
+1 858-966-3003  
Cheryl Liberatore  
Director, Communications  
+1 858-966-3045  
ir@teamreva.com

**Australia****Investor Enquiries:**

Inteq Limited  
Kim Jacobs  
+61 438 217 279  
Andrew Cohen  
+61 408 333 452

**Australia****Media Enquiries:**

Buchan Consulting  
Rebecca Wilson  
+61 3 9866 4722